Clinical Trials Logo

Cancer of Stomach clinical trials

View clinical trials related to Cancer of Stomach.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05311176 Active, not recruiting - Gastric Cancer Clinical Trials

A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

nextHERIZON
Start date: August 17, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, signal generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas.

NCT ID: NCT03775525 Active, not recruiting - Breast Cancer Clinical Trials

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

GEN602
Start date: March 1, 2019
Phase: Phase 1
Study type: Interventional

This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma

NCT ID: NCT03347162 Active, not recruiting - Cancer Clinical Trials

Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer

Start date: December 1, 2017
Phase:
Study type: Observational

PURPOSE: To determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with GI-HEP cancer from point of diagnosis and throughout the treatment trajectory. GI-HEP: Patients with tumors of the upper gastrointestinal or hepatobiliary tract, specifically tumors of the esophagus, gastro-esophageal junction, stomach, primary tumors of the liver or biliary tract, as well as colorectal liver metastasis or tumors of the pancreas.

NCT ID: NCT00165048 Active, not recruiting - Cancer of Stomach Clinical Trials

Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the effect of selective COX-II inhibitor in patients with regionally disseminated stomach cancer treated by palliative resection (so called R1 or R2 gastrectomy).

NCT ID: NCT00164892 Active, not recruiting - Cancer of Stomach Clinical Trials

Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy of selective COX-II inhibitor in patients with curative resection performed for locally advanced stomach cancer.